Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model

Figure 2 Effect of dexamethasone, cholesteryl butyrate and dexamethasone cholesteryl butyrate-solid lipid nanoparticles on human vascular endothelial cell adhesiveness to Jurkat cells. Human vascular endothelial cells were pre-activated with IL-1β (0.01 μmol/L) for 1 h and then exposed or not exposed to increasing concentrations of Dx (2.5, 25 and 250 nmol/L), Cb (0.1, 1 and 10 μmol/L) and DxCb-SLN (2.5 nmol/L:0.1 μmol/L, 25 nmol/L:1 μmol/L and 250 nmol/L:10 μmol/L) for 24 h and then incubated with Jurkat for 1 h. ^bP < 0.01, vs Dx; ^dP < 0.01, vs Cb. Dx: Dexamethasone; Cb: Cholesteryl butyrate; DxCb-SLN: Dexamethasone cholesteryl butyrate-solid lipid nanoparticles.